跳至主導覽 跳至搜尋 跳過主要內容

Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization

  • Wei Teng
  • , Y. C. Hsieh
  • , K. W. Lui
  • , W. T. Chen
  • , C. F. Hung
  • , C. H. Huang
  • , Y. C. Chen
  • , W. J. Jeng*
  • , C. C. Lin
  • , C. Y. Lin
  • , S. M. Lin
  • , I-Shyan Sheen
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • National Yang Ming Chiao Tung University
  • Chang Gung University

研究成果: 期刊稿件 › 文章 › 同儕審查

11 引文 斯高帕斯(Scopus)

摘要

Adjuvant pegylated interferon plus ribavirin treatment (PegIFN/RBV) reduces recurrence and prolongs survival in early stage hepatocellular carcinoma (HCC) patients with chronic hepatitis C (CHC) infection receiving resection or ablation. However, the impact of antiviral therapy in intermediate and advanced stage of CHC-HCC patients is uncertain. This study aimed to investigate the impact PegIFN/RBV treatment on recurrence-free interval and survival in patients with HCC receiving transarterial chemoembolization (TACE). From 2010 to 2013, 274 CHC patients from a 1073 patient-based cohort composed of freshly diagnosed HCC and receiving TACE treatment the Chang Gung Memorial Hospital, Linkou Medical Center were recruited. Propensity score matching (PSM) (age, gender, AST to Platelet Ratio Index (APRI), tumour size, tumour number and Child-Turcotte-Pugh score) with the ratio 1:2 for patients with and without PegIFN/RBV treatment was performed. Statistics were performed with SPSS V.20 (IBM, USA). After matching, 153 patients were analysed and 27 patients (17.6%) achieved sustained virologic response (SVR). The 2-year cumulative overall survival rate and recurrence-free survival rate among patients with SVR, non-SVR, and untreated were 85.2% vs 58.3% vs 69.6% (P=.001) and 73.3% vs 53.8% vs 58.5% (P=.013). By Cox regression analysis, non-SVR, untreated, increase CTP score and nonresponder to TACE were independent factors related to mortality. The SVR achieved by PegIFN/RBV treatment markedly improves survival and reduces tumour recurrence in CHC-HCC patients receiving TACE treatment after complete response.

原文英語
頁(從 - 到)1160-1167
頁數8
期刊Journal of Viral Hepatitis
卷24
發行號12
DOIs
出版品狀態已出版 - 12 2017

文獻附註

Publisher Copyright:
© 2017 John Wiley & Sons Ltd

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization」主題。共同形成了獨特的指紋。

引用此